An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers. (Record no. 13085)

MARC details
000 -LEADER
fixed length control field 03838nam a22004697a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 230815s20232023 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 0009-9236
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1002/cpt.2957 [doi]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 37303270
245 ## - TITLE STATEMENT
Title An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers.
251 ## - Source
Source Clinical Pharmacology & Therapeutics. 114(2):275-287, 2023 08.
252 ## - Abbreviated Source
Abbreviated source Clin Pharmacol Ther. 114(2):275-287, 2023 08.
253 ## - Journal Name
Journal name Clinical pharmacology and therapeutics
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2023
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2024
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Publication date 2023 08
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status ppublish
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Medline status MEDLINE
266 ## - Date added to catalog
Date added to catalog 2023-08-15
520 ## - SUMMARY, ETC.
Abstract Pharmacogenetics can improve clinical outcomes by reducing adverse drug effects and enhancing therapeutic efficacy for commonly used drugs that treat a wide range of cardiovascular diseases. One of the major barriers to the clinical implementation of cardiovascular pharmacogenetics is limited education on this field for current healthcare providers and students. The abundance of pharmacogenetic literature underscores its promise, but it can also be challenging to learn such a wealth of information. Moreover, current clinical recommendations for cardiovascular pharmacogenetics can be confusing because they are outdated, incomplete, or inconsistent. A myriad of misconceptions about the promise and feasibility of cardiovascular pharmacogenetics among healthcare providers also has halted clinical implementation. Therefore, the main goal of this tutorial is to provide introductory education on the use of cardiovascular pharmacogenetics in clinical practice. The target audience is any healthcare provider (or student) with patients that use or have indications for cardiovascular drugs. This tutorial is organized into the following 6 steps: (1) understand basic concepts in pharmacogenetics; (2) gain foundational knowledge of cardiovascular pharmacogenetics; (3) learn the different organizations that release cardiovascular pharmacogenetic guidelines and recommendations; (4) know the current cardiovascular drugs/drug classes to focus on clinically and the supporting evidence; (5) discuss an example patient case of cardiovascular pharmacogenetics; and (6) develop an appreciation for emerging areas in cardiovascular pharmacogenetics. Ultimately, improved education among healthcare providers on cardiovascular pharmacogenetics will lead to a greater understanding for its potential in improving outcomes for a leading cause of morbidity and mortality. Copyright © 2023 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Cardiovascular Agents
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Cardiovascular Diseases
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Drug-Related Side Effects and Adverse Reactions
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cardiovascular Agents/ae [Adverse Effects]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cardiovascular Diseases/dt [Drug Therapy]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cardiovascular Diseases/ge [Genetics]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Health Personnel
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Pharmacogenetics/ed [Education]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Indexing Automated
656 ## - INDEX TERM--OCCUPATION
Department MedStar Health
656 ## - INDEX TERM--OCCUPATION
Department Pharmacogenomics
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
657 ## - INDEX TERM--FUNCTION
Medline publication type Research Support, N.I.H., Extramural
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Smith, D Max
Institution Code MSH
790 ## - Authors
All authors Aminkeng F, Castrichini M, Cavallari LH, Crews KR, Duarte JD, Friede KA, Hoffecker G, Huang Y, Lteif C, Luzum JA, Murphy WA, Nguyen NHK, Oni-Orisan A, Smith DM, Tantisira K, Tuteja S, Voora D, Whirl-Carrillo M
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1002/cpt.2957">https://dx.doi.org/10.1002/cpt.2957</a>
Public note https://dx.doi.org/10.1002/cpt.2957
858 ## - ORCID
Name https://orcid.org/0000-0003-3667-2936
ORCID text Smith, D Max
Orcid <a href="https://orcid.org/0000-0003-3667-2936">https://orcid.org/0000-0003-3667-2936</a>
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article

No items available.

Powered by Koha